Search - tctmd.com

Displaying 101 - 120 of 331

Sort: Relevancy | Date

News Industry News

Abbott Announces European Approval Of Two Life-Saving Heart Devices For Babies And Children

September 17, 2019

News Daily News

Post-MI Mechanical Complications Infrequent but Deadly

Todd Neale

September 16, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

Podcast TCTMD Talking Points

PREPARE-CALC: A Randomized Trial of High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions

September 04, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

Todd Neale

September 04, 2019

News Conference News ESC 2019

Ruling Out MI Safe With 0/1-Hour High-Sensitivity Troponin: RAPID-TNT

Michael O'Riordan

September 03, 2019

News Conference News ESC 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

MITRA-FR at 2 Years: Still No Benefit of MitraClip Over Meds

Shelley Wood

September 02, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

News Daily News

Use of IVC Filters for DVT Peaked in 2010 but Remains High

Michael O'Riordan

August 28, 2019

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Caitlin E. Cox

August 27, 2019

News Daily News

Learning Curve for New CTO Operators: Some Reassurances, Some Caveats

L.A. McKeown

August 26, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Advertisement

Abbott Announces European Approval Of Two Life-Saving Heart Devices For Babies And Children

Post-MI Mechanical Complications Infrequent but Deadly

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

PREPARE-CALC: A Randomized Trial of High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

Ruling Out MI Safe With 0/1-Hour High-Sensitivity Troponin: RAPID-TNT

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

MITRA-FR at 2 Years: Still No Benefit of MitraClip Over Meds

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Use of IVC Filters for DVT Peaked in 2010 but Remains High

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Learning Curve for New CTO Operators: Some Reassurances, Some Caveats

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content